Omalizumab in patients with severe form of chronic skin disease

Novartis has announced late-breaking results showing omalizumab met all primary and secondary endpoints of a pivotal Phase III safety registration study in chronic spontaneous urticaria (CSU), a chronic and debilitating form of hives with limited approved treatment options.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Source Type: news